Hilde Marie Torgauten

Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination

Marton König, Hilde Marie Torgauten, The Trung Tran et al. · JAMA Neurology · 2022 · 85 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +9

Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations

Marton König, Åslaug Rudjord Lorentzen, Hilde Marie Torgauten et al. · Journal of Neurology Neurosurgery & Psychiatry · 2021 · 56 citations · Full text

Life Sciences, Immunology, Autoimmunity +13

Safety and efficacy of rituximab as first- and second line treatment in multiple sclerosis – A cohort study

Hilde Marie Torgauten, Kjell‐Morten Myhr, Stig Wergeland et al. · Multiple Sclerosis Journal - Experimental Translational and Clinical · 2021 · 40 citations · Full text

Pharmacy, Neurology, Pharmacotherapy +15

Predictors of hospitalization due to infection in rituximab-treated MS patients

Jakob Rishovd Karlowicz, Mattias Klakegg, Jan Aarseth et al. · Multiple Sclerosis and Related Disorders · 2023 · 13 citations · Full text

Life Sciences, Hematology, Immunology +14